In the most recent trading session, Ulta Beauty (ULTA) closed at $517.66, indicating a -1.3% shift from the previous trading day.

OneSpan (OSPN) closed the most recent trading day at $16, moving +1.27% from the previous trading session.

Apple (AAPL) reached $262.82 at the closing of the latest trading day, reflecting a +1.25% change compared to its last close.

Synopsys (SNPS) concluded the recent trading session at $464.4, signifying a +1.82% move from its prior day's close.

In the closing of the recent trading day, Cameco (CCJ) stood at $88.13, denoting a +2.12% move from the preceding trading day.

Integer Holdings faces a sharp valuation reset after revising 2026 guidance to flat sales and earnings, shocking investors. Despite strong organic growth and margin recovery in 2023-2024-2025, Integer´s 2026 outlook signals a sudden halt in momentum. Leverage remains elevated and CEO transition adds uncertainty, compounding concerns after aggressive customer demand changes.

Investors may want to consider buying Mag 7 stock and the AI hyperscaler Amazon before a potential Q3 earnings breakout.

Shares of Hims & Hers Health Inc. NYSE: HIMS have been the hottest thing in the medical sector, and for good reason. The company's fundamentals are highly attractive for investors who prefer to acquire growth stories early, before they become too large to price in further expansion.

Wendy's (WEN) continues to underperform major fast-food peers, with especially weak traffic trends in key markets despite value-focused promotions. WEN's heavy reliance on breakfast and new chicken strip offerings have failed to drive meaningful traffic or value perception versus competitors like McDonald's and Chick-fil-A. Management's recent capital allocation shifts and promotional efforts have yet to address core issues of traffic decline and competitive pressure from casual dining.

Nipocalimab, a first-in-class FcRn blocker being investigated for SjD, met its primary endpoint in the Phase 2 DAHLIAS study with statistically significant improvement in ClinESSDAI score , which is based on 11 key systemic disease domains, at Week 24 versus placebo Critical patient-reported SjD symptoms including dryness, pain and fatigue trended towards greater improvement in the nipocalimab-treated group compared to placebo-treated patients Nipocalimab is the only investigational treatment to be granted Breakthrough Therapy Designation (BTD) by U.S. FDA for the treatment of adults living with moderate-to-severe SjD, and the Phase 3 DAFFODIL study is currently enrolling patients SPRING HOUSE, Pa. …

AGF U.S. Market Neutral Anti-Beta Fund (BTAL) is long in 200 low-beta stocks and short in 200 high-beta stocks. BTAL has value characteristics and low company risk, but its track record is uncompelling, with negative return since 2011. FTLS stands out as a superior long-short ETF alternative for investors seeking risk-adjusted performance.

Although the revenue and EPS for Halliburton (HAL) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of MarineMax, Inc. (NYSE: HZO) resulting from allegations that MarineMax may have issued materially misleading business information to the investing public. So What: If you purchased MarineMax securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. Th.

NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Designer Brands Inc. (NYSE: DBI) resulting from allegations that Designer Brands may have issued materially misleading business information to the investing public.

CNBC's “Fast Money” team share their final trades of the day.

Netflix has shut down the studio behind its mobile game "Squid Game: Unleashed", amid a shift in strategy for its video gaming unit.

Orchid Island Capital, Inc. (NYSE:ORC ) Q3 2025 Earnings Call October 24, 2025 10:00 AM EDT Company Participants Robert Cauley - Chairman, President & CEO Jerry Sintes - VP & Treasurer George Haas - CFO, Chief Investment Officer, Secretary & Director Conference Call Participants Jason Weaver - JonesTrading Institutional Services, LLC, Research Division Eric Hagen - BTIG, LLC, Research Division Mikhail Goberman - Citizens JMP Securities, LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Orchid Island Capital Third Quarter 2025 Earnings Conference Call.

Core Scientific, Inc. (CORZ) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to a loss of $0.13 per share a year ago.

Shares of a major automaker surged Friday on a strong earnings report, while a shoes and apparel maker lost ground after warning tariffs and higher prices could discourage shoppers.

In the world of defense investing, some of the best opportunities come not from discovering new names, but from re-evaluating essential companies that Wall Street may be underpricing relative to their strategic value.